It has already been heralded as the ‘turning point’ in the decades-long war against Alzheimer’s.
But questions about whether donanemab — and two similar drugs — are really the answer to combating the devastating disease remain unanswered.
Landmark trial findings published today revealed that donanemab, given as a once-monthly infusion, slowed the decline of Alzheimer’s by up to 60 per cent.
Patients in the earliest stages of the memory-robbing disease were spared from the inevitable worsening of their symptoms.
Pharmaceutical
